ArticleBMC biotechnology2026
Integrated structure-based and systems-level identification of PDE9A inhibitors for heart failure with preserved ejection fraction.
Article in BMC biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure with preserved ejection fraction (HFpEF) is a complex and increasingly prevalent cardiovascular disorder with limited effective therapeutic options. Dysregulation of cyclic guanosine monophosphate (cGMP) signaling has been implicated in its pathophysiology. Phosphodiesterase 9A (PDE9A), a cGMP-specific enzyme, has emerged as a potential therapeutic target due to its role in nitric oxide-independent signaling pathways associated with myocardial dysfunction.
methodsThis study employed an integrated computational framework combining multi-conformational docking, pharmacophore modeling, pharmacophore validation using active-decoy screening, molecular dynamics simulations, and systems-level analyses to identify potential PDE9A inhibitors. Three crystal structures of PDE9A (4GH6, 4Y87, and 6LZZ) were analyzed for physicochemical properties, structural validation, and binding site prediction. Pharmacophore-guided virtual screening of PubChem-derived compounds was followed by active-decoy validation, ADMET evaluation, molecular docking, redocking validation, protein-ligand interaction analysis, and 500 ns molecular dynamics simulations.
resultsSeveral compounds demonstrated favorable binding affinities and pharmacokinetic profiles. Among them, EVPMO-PurHD exhibited the strongest binding affinity (- 10.1 kcal/mol) and suggested stable interaction behavior during the equilibrated phase of the simulation, following an initial conformational adjustment period, as indicated by RMSD stabilization and sustained intermolecular interaction.
conclusionThe findings indicate that the identified compounds represent promising computationally predicted candidates for PDE9A inhibition, supported by favorable binding affinity, stability, and pharmacokinetic profiles. However, further experimental validation through biochemical and in vitro/in vivo studies is required to confirm their therapeutic potential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.